Company intelligence / Profile preview

BriaCell Therapeutics Corp.

West Vancouver, British Columbia, Canadafutunn.com ↗

Ownership: Public · BCTX
Employees: ~16
Development stage: Phase 2

Overview

Phase 2 clinical study showed doubling of progression-free-survival (PFS) and clinical benefit in metastatic breast cancer. Lead candidate Bria-IMT™ is in a pivotal Phase 3 study for metastatic breast cancer and has been awarded Fast Track status by the FDA. Bria-OTS™ is in Phase 1/2 trials for breast cancer with plans to expand to prostate and other cancers.

Therapeutic areas: Oncology
Modalities: Cell-based immunotherapies
Industry: Biotech

Drug pipeline

6 assets

SV-BR-1-GM

5 more assets in the full pipeline.

Request access →

Partnerships

National Cancer Institute (NCI)BeiGene (for tislelizumab)

Financials

Market cap: $31.3M
Total revenue: $0
Enterprise value: $8.5M

Beyond the preview

Go deeper on BriaCell Therapeutics Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BriaCell Therapeutics Corp..

Explore the full profile